Urotensin-II levels in children with minimal change nephrotic syndrome

Balat, Ayşe; Pakir, I. Halil; Gok, F; Anarat, Ruksen; Şahinöz, Saime

doi:10.1007/s00467-004-1716-5

Cited by 19 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously, we investigated the level of U-II in children with MCNS, [11] and to our knowledge, there is no previous study about the possible role of U-II in other childhood glomerulonephritis. As has been demonstrated, activated components of the immune system initiate most forms of human glomerulonephritis.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Urotensin-II Immunoreactivity in Children with Chronic Glomerulonephritis

et al. 2007

View full text Add to dashboard Cite

Background. Human urotensin-II (hU-II) is one of the most potent vasoconstrictors in mammals. To our knowledge, there is no study about the role of U-II in childhood glomerulonephritis.We first determined the expression of h U-II in kidneys of children with chronic glomerular diseases. Methods. Normal human kidneys were obtained from postmortem biopsies and compared with the kidney biopsy specimens of 24 children with membranoproliferative glomerulonephritis (MPGN) and 6 children with membranous GN. Kidney needle biopsies in 10% neutral buffered-formalin prior to routine processing through to embedded blocking sections were cut, and immunohistochemical reactions were performed on parafinembedded tissue by an avidin-biotin peroxidase complex method. The antibodies used in the present study were hU-II. The positivities were revealed as weak (+), moderate (++), and severe (+++), according to the color intensity. Results. In kidneys of children with MPGN, differently fom the normal kidneys, more dense U-II immunoreactivity was seen in the glomerular basement membrane (GBM), glomerular mesangium, Bowman capsule, and tubules. Interestingly, we also observed U-II immunoreactivity in crescents. In children with MGN, U-II was mostly seen in GBM and Bowman capsule. Conclusion. Our findings suggest that U-II may have a possible autocrine/paracrine function in the kidneys, and may be an important target molecule in studying renal pathophsiology.

show abstract

Section: Discussionmentioning

confidence: 97%

“…Recently, we also demonstrated that U-II was present in plasma and urine samples of children with minimal change nephrotic syndrome. [11] The purpose of present study was to determine the expression of h U-II in kidneys of children with chronic glomerular diseases.…”

Section: Introductionmentioning

confidence: 99%

Urotensin-II Immunoreactivity in Children with Chronic Glomerulonephritis

et al. 2007

View full text Add to dashboard Cite

show abstract

“…40 Thus, similar to other autocoids, UTN may also act as a circulating hormone. Plasma UTN is much increased in patients with renal diseases, including minimal change glomerulopathy, 41 diabetic nephropathy, 42 chronic kidney disease in general, 24 and ESRD in particular. 19,20 …”

Section: Urotensin In Renal Diseases and In Esrdmentioning

confidence: 99%

Urotensin II and Cardiomyopathy in End-Stage Renal Disease

et al. 2008

View full text Add to dashboard Cite

Abstract-Circulating urotensin (UTN) is increased in patients with heart failure and in patients with renal diseases, and UTN antagonism is currently considered as a potential treatment for these conditions. Contrary to this contention, studies in end-stage renal disease suggest that, perhaps because of interference with sympathetic and NO systems, UTN may be cardioprotective. (UTN) is a cyclic undecapeptide that is widely distributed in several organ systems, including the vascular system and the heart. 1 UTN is a quite strong inotrope in isolated myocardial tissues like human right atrial trabeculae 2 and rat left ventricular (LV) papillary muscles, 3 but in vivo it reduces cardiac performance when administered on a chronic basis in the rat 4 and causes a marked cardiodepressant effect in acute experiments in primates 5,6 concomitant with a decrease in blood pressure. Because UTN promotes myocardial cell hypertrophy in vitro and activates fibrogenesis, 7,8 high gene expression of this peptide at myocardial level 9 and high circulating UTN in patients with heart failure 10 -13 have initially been considered as potentially noxious in these patients. However, recent observations in a chronic volume overload model in the rat 14 indicate that subcutaneous administration of UTN on a chronic basis may help to preserve myocardial contractility in this model. These observations go along with findings in the same model showing that bolus UTN injections exert favorable, NOdependent, renal hemodynamic effects. 15 On the other hand, UTN is reduced in patients with acute coronary syndromes, 16 and low UTN predicts adverse clinical outcomes and death in patients after myocardial infarction. 17 Overall it remains largely undefined whether UTN has a role in LV disorders in humans.End-stage renal disease (ESRD) represents an intriguing model to explore the role of UTN in cardiovascular (CV) diseases in humans because cardiomyopathy is pervasive in this condition 18 and because UTN attains high plasma levels in ESRD. 19,20 In previous studies in this population we found that UTN is inversely, rather than directly, related to CV stress hormones like norepinephrine and neuropeptide Y 20 and to the endogenous inhibitor of NO synthesis, asymmetrical dimethylarginine (ADMA). 21 UTN is a potent NOdependent vasodilator in pulmonary and mesenteric circulation in humans, 22 and we hypothesized that these links may

show abstract

“…Moreover, patients, in relapse and in remission, had lower plasma and urine UII concentrations compared to healthy controls. Plasma UII had a strong correlation with plasma albumin, only in remission [22]. More dense UII immunoreactivity in renal biopsy specimens of children with membranoproliferative glomerulonephritis compared to healthy kidneys has been found and a possible autocrine/paracrine function of UII in kidneys has been considered [23].…”

Section: Discussionmentioning

confidence: 99%

Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study

et al. 2017

View full text Add to dashboard Cite

BackgroundIncreased plasma Urotensin II (UII) levels have been found in adults with renal diseases. Studies in children are scarce. The objective of the study is to estimate plasma UII levels in subjects with chronic kidney disease (CKD) stages 3 to 5 and renal transplant recipients (RTR). In addition, the correlation of UII with anthropometric features and biochemical parameters was assessed.MethodsFifty-four subjects, aged 3 to 20 years old, 23 with CKD, 13 with end-stage kidney disease (ESKD) undergoing hemodialysis (HD) and 18 RTR were enrolled. A detailed clinical evaluation was performed. Biochemical parameters of renal and liver function were measured. Plasma UII levels were measured in all patients and in 117 healthy controls, using a high sensitive enzyme immunoassay (EIA) kit. All data were analyzed using STATA™ (Version 10.1).ResultsMedian UII and mean log-transformed UII levels were significantly higher in CKD and RTR patients compared to healthy subjects (p < 0.001). HD patients had higher but not statistically significant UII and log-UII levels than controls. UII levels increased significantly at the end of the HD session and were higher than controls and in line to those of other patients. The geometric scores of UII in HD (before dialysis), CKD and RTR patients increased respectively by 42, 136 and 164% in comparison with controls. Metabolic acidosis was associated with statistical significant change in log-UII levels (p = 0.001). Patients with metabolic acidosis had an increase in UII concentration by 76% compared to those without acidosis.ConclusionsChildren and adolescents with CKD, particularly those who are not on HD and RTR, have significantly higher levels of UII than healthy subjects. UII levels increase significantly at the end of the HD session. The presence of metabolic acidosis affects significantly plasma UII levels.

show abstract

Urotensin-II levels in children with minimal change nephrotic syndrome

Cited by 19 publications

References 16 publications

Urotensin-II Immunoreactivity in Children with Chronic Glomerulonephritis

Urotensin-II Immunoreactivity in Children with Chronic Glomerulonephritis

Urotensin II and Cardiomyopathy in End-Stage Renal Disease

Plasma Urotensin II levels in children and adolescents with chronic kidney disease: a single-centre study

Contact Info

Product

Resources

About